HC Wainwright Has Optimistic Outlook of SGMO Q3 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Investment analysts at HC Wainwright increased their Q3 2025 earnings estimates for shares of Sangamo Therapeutics in a note issued to investors on Wednesday, May 14th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings per share of ($0.08) for the quarter, up from their previous forecast of ($0.11). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2025 earnings at ($0.17) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.04) EPS.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $6.44 million for the quarter, compared to analysts’ expectations of $7.90 million.

A number of other equities analysts have also recently commented on SGMO. Barclays dropped their price objective on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, May 14th. Royal Bank of Canada reissued a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, Truist Financial dropped their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $4.50.

Sangamo Therapeutics Stock Up 4.4%

Shares of NASDAQ:SGMO opened at $0.47 on Monday. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18. The stock has a market capitalization of $107.72 million, a P/E ratio of -0.63 and a beta of 1.46. The firm has a fifty day simple moving average of $0.73 and a two-hundred day simple moving average of $1.31.

Institutional Investors Weigh In On Sangamo Therapeutics

Large investors have recently made changes to their positions in the stock. E Fund Management Co. Ltd. purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at $25,000. JPMorgan Chase & Co. boosted its holdings in Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 21,793 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Sangamo Therapeutics by 2,319.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in Sangamo Therapeutics in the fourth quarter valued at $28,000. Finally, Captrust Financial Advisors purchased a new stake in Sangamo Therapeutics in the fourth quarter valued at $30,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.